A Phase 2 interventional study of SPM 962 in Idiopathic Restless Legs Syndrome, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 8 sites in Japan. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2014-04-25.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing rotigotine in Restless Legs Syndrome — none open to participants now, none under way, none of them phase 3. rotigotine · Restless Legs Syndrome.
Among the 19 studies testing rotigotine in Restless Legs Syndrome, this one is the 7th largest by enrollment, is one of 2 that started in 2008, is one of 6 in phase 2, and was the 8th registered.
259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.
Browse Restless Legs Syndrome studies →None of the 19 studies testing rotigotine in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.
This study: 20 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2008.
This study's enrollment of 230 is above the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.
Median enrollment 130 across the 19 interventional studies. Of the 19 that completed or were terminated, 13 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 19 have an industry lead sponsor. The 7 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Otsuka Holdings Co., Ltd. has 3 studies filed under Restless Legs Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing rotigotine in Restless Legs Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to investigate efficacy and safety of SPM 962 in Japanese RLS patients in a multi-center, placebo-controlled double-blind parrallel group comparative study following once-daily multiple transdermal doses of SPM 962 within a range of 2.25 to 6.75 mg/day. Recommended maintainance dose range is also to be investigated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The following subject will be included in the study
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
inactive placebo
Drug: SPM 962
2.25 mg first week: 2.25 mg 1 sheet plus placebo 1 sheet 2nd to 6th week :2.25mg 1 sheet plus placebo 2 sheets
Drug: SPM 962
4.5 mg/body first week : 2.25 mg 2 sheets 2nd to 6th week : 2.25 mg 2 sheets pus placebo 1 sheet
Drug: SPM 962
6.75 mg/body first week : 2.25 mg 2 sheets 2nd to 6th week : 2.25 mg 3sheets
Drug: SPM 962
transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks
Also known as: rotigotine
Change of International Restless Legs Syndrome Study Group Rating Scale (IRLS) Score From the Baseline to the End of Titration/Maintenance Period
IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none). The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement.
Time frame: Baseline, end of maintenance period at 6 weeks
Clinical Global Impression (CGI) Severity
CGI is a clinician-reported scale for assessing severity of illness. The sale scoring criteria are 1: Normal, not at all ill, 2: Borderline ill, 3: Mildly ill, 4: Moderately ill, 5: Markedly ill, 6: Severely ill, 7: Among the most extremely ill patients.
Time frame: Baseline, 2 weeks, 4 weeks and 6 weeks. The data at 6 weeks after dosing is shown.
Patient Global Impression (PGI) Improvement
The PGI-I is a self-rated 7-point scale, with scores ranging from 1 (very much improved) to 7 (very much worse), that assesses the improvement or worsening of a patient's illness relative to baseline at the beginning of the intervention. Scores: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Moderate and marked improvement = score of 1 or 2, Without improvement = score of 4, Marked and moderate aggravation = score of 6 or 7.
Time frame: Baseline, 4 weeks and 6 weeks. The data at 6 weeks after dosing is shown.
The Pittsburgh Sleep Quality Index (PSQI)
PSQI is a scale for assessing severity of sleep disorders. The score ranges from 0 to 21. 0 indicates "no difficulty" and 21 indicates "severe difficulty". A decrease in the scores means improvement. The data at 6 weeks after dosing is shown.
Time frame: Baseline, every two weeks
Medical Outcome Study (MOS) Short-Form 36-Item Health Survey (SF-36)
Mean Change from baseline in MOS Short Form SF-36 to 6 weeks after dosing. SF-36 is a scale for assessing health status in clinical practice and research. The scores of 36 questions are summarized into 7 sub-scales. In each sub-scale which range is 0-100, a higher score indicates a better health status. Thus a increase in the scores means improvement.
Time frame: Baseline, every two weeks
IRLS Each Parameter
IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none). The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement. The percentage of subjects with -3 or -4 changes from baseline in each parameter at 6 weeks after dosing is shown.
Time frame: Baseline, every two weeks
| Milestone | Placebo | 2.25 mg/Day | 4.5 mg/Day | 6.75 mg/Day |
|---|---|---|---|---|
| Started | 58 | 57 | 58 | 57 |
| Completed | 55 | 53 | 56 | 42 |
| Not completed | 3 | 4 | 2 | 15 |
| Withdrew: Adverse event | 0 | 2 | 1 | 9 |
| Withdrew: Lack of efficacy | 1 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 2 |
| Withdrew: Discontinuation criteria | 2 | 1 | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 |
IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none). The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement.
| scores on a scale | Placebo | 2.25 mg/Day | 4.5 mg/Day | 6.75 mg/Day |
|---|---|---|---|---|
| Change of International Restless Legs Syndrome Study Group Rating Scale (IRLS) Score From the Baseline to the End of Titration/Maintenance Period | -9.8 ± 7.2 | -10.7 ± 6.3 | -14.4 ± 7.2 | -14.1 ± 8.8 |
CGI is a clinician-reported scale for assessing severity of illness. The sale scoring criteria are 1: Normal, not at all ill, 2: Borderline ill, 3: Mildly ill, 4: Moderately ill, 5: Markedly ill, 6: Severely ill, 7: Among the most extremely ill patients.
| Percentage of Participants | Placebo | 2.25 mg/Day | 4.5 mg/Day | 6.75 mg/Day |
|---|---|---|---|---|
| Decreased | 73.7 | 83.6 | 92.9 | 86.3 |
| Increased | 1.8 | 1.8 | 0.0 | 3.9 |
| Decreased to 1 or 2 | 12.3 | 18.2 | 41.1 | 39.2 |
| Subjects with CGI score 5 | 8.8 | 12.7 | 3.6 | 7.8 |
| Subjects without improvement | 26.3 | 16.4 | 7.1 | 13.7 |
| 4 at baseline and stayed at 4 | 26.5 | 13.3 | 10.7 | 10.7 |
| 5 at baseline and decreased to 1 or 2 | 0 | 24.0 | 46.4 | 30.4 |
The PGI-I is a self-rated 7-point scale, with scores ranging from 1 (very much improved) to 7 (very much worse), that assesses the improvement or worsening of a patient's illness relative to baseline at the beginning of the intervention. Scores: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Moderate and marked improvement = score of 1 or 2, Without improvement = score of 4, Marked and moderate aggravation = score of 6 or 7.
| Percentage of Participants | Placebo | 2.25 mg/Day | 4.5 mg/Day | 6.75 mg/Day |
|---|---|---|---|---|
| Moderate and marked improvement | 55.4 | 70.4 | 82.1 | 85.4 |
| Without improvement | 17.9 | 3.7 | 3.6 | 6.3 |
| Moderate and marked aggravation | 0.0 | 0.0 | 1.8 | 0.0 |
PSQI is a scale for assessing severity of sleep disorders. The score ranges from 0 to 21. 0 indicates "no difficulty" and 21 indicates "severe difficulty". A decrease in the scores means improvement. The data at 6 weeks after dosing is shown.
| Percentage of Participants | Placebo | 2.25 mg/Day | 4.5 mg/Day | 6.75 mg/Day |
|---|---|---|---|---|
| Subjects with ≥60% decrease | 7.1 | 16.7 | 23.2 | 23.4 |
| Subjects with ≥50% decrease | 25.0 | 27.8 | 39.3 | 44.7 |
Mean Change from baseline in MOS Short Form SF-36 to 6 weeks after dosing. SF-36 is a scale for assessing health status in clinical practice and research. The scores of 36 questions are summarized into 7 sub-scales. In each sub-scale which range is 0-100, a higher score indicates a better health status. Thus a increase in the scores means improvement.
| Scores on a scale | Placebo | 2.25 mg/Day | 4.5 mg/Day | 6.75 mg/Day |
|---|---|---|---|---|
| Physical functioning | 1.1 ± 8.1 | 1.6 ± 9.6 | 2.8 ± 12.7 | 0.1 ± 6.1 |
| Role physical | -0.4 ± 18.0 | 1.7 ± 18.7 | 1.3 ± 15.8 | 0.9 ± 11.9 |
| Bodily pain | -1.7 ± 25.0 | 5.0 ± 28.0 | 1.7 ± 27.4 | 12.6 ± 19.7 |
| General health | 3.4 ± 16.4 | 2.5 ± 10.5 | 4.6 ± 14.8 | 4.9 ± 12.9 |
| Vitality | 6.3 ± 16.6 | 6.5 ± 17.2 | 3.6 ± 19.9 | 6.5 ± 18.6 |
| Social functioning | -0.2 ± 19.3 | 4.4 ± 17.0 | 1.1 ± 18.4 | 4.0 ± 12.5 |
| Role emotional | -0.1 ± 18.4 | 5.7 ± 18.4 | 4.2 ± 18.7 | 0.7 ± 16.6 |
IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none). The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement. The percentage of subjects with -3 or -4 changes from baseline in each parameter at 6 weeks after dosing is shown.
| Percentage of Participants | Placebo | 2.25 mg/Day | 4.5 mg/Day | 6.75 mg/Day |
|---|---|---|---|---|
| -4 (RLS discomfort) | 0.0 | 0.0 | 0.0 | 3.9 |
| -3 (RLS discomfort) | 7.0 | 1.8 | 16.1 | 19.6 |
| -4 (need to move around due to RLS symptoms) | 0.0 | 0.0 | 3.6 | 2.0 |
| -3 (need to move around due to RLS symptoms) | 10.5 | 9.1 | 16.1 | 25.5 |
| -4 (discomfort relief by moving around) | 0.0 | 0.0 | 1.8 | 2.0 |
| -3 (discomfort relief by moving around) | 7.0 | 9.1 | 26.8 | 13.7 |
| -4 (severity of RLS as a whole) | 0.0 | 0.0 | 0.0 | 2.0 |
| -3 (severity of RLS as a whole) | 1.8 | 3.6 | 12.5 | 19.6 |
| -4 (RLS symptoms frequency) | 1.8 | 3.6 | 3.6 | 9.8 |
| -3 (RLS symptoms frequency) | 7.0 | 7.3 | 26.8 | 19.6 |
| -4 (average duration of RLS symptoms) | 0.0 | 0.0 | 0.0 | 0.0 |
| -3 (average duration of RLS symptoms) | 3.5 | 0.0 | 7.1 | 7.8 |
| -4 (severity of sleep disturbance) | 0.0 | 0.0 | 1.8 | 2.0 |
| -3 (severity of sleep disturbance) | 3.5 | 12.7 | 12.5 | 21.6 |
| -4 (tiredness or sleepiness during the day) | 0.0 | 0.0 | 0.0 | 0.0 |
| -3 (tiredness or sleepiness during the day) | 1.8 | 7.3 | 5.4 | 11.8 |
| -4 (severity of impact on daily affaires) | 0.0 | 1.8 | 1.8 | 2.0 |
| -3 (severity of impact on daily affaires) | 5.3 | 3.6 | 3.6 | 7.8 |
| -4 (severity of mood disturbance) | 0.0 | 0.0 | 1.8 | 0.0 |
| -3 (severity of mood disturbance) | 5.3 | 5.5 | 1.8 | 7.8 |
Collected over 7 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/58 (0%) | 29/58 (50%) |
| 2.25 mg/Day | — | 0/57 (0%) | 37/57 (64.9%) |
| 4.5 mg/Day | — | 0/58 (0%) | 50/58 (86.2%) |
| 6.75 mg/Day | — | 0/57 (0%) | 44/57 (77.2%) |
| Event | Placebo | 2.25 mg/Day | 4.5 mg/Day | 6.75 mg/Day |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 8/58 | 19/57 | 25/58 | 27/57 |
| NasopharyngitisInfections and infestations | 14/58 | 12/57 | 15/58 | 14/57 |
| SomnolencePsychiatric disorders | 3/58 | 6/57 | 11/58 | 12/57 |
| VomitingGastrointestinal disorders | 1/58 | 4/57 | 6/58 | 11/57 |
| Application Site PruritusGeneral disorders | 2/58 | 8/57 | 11/58 | 10/57 |
| HeadacheNervous system disorders | 1/58 | 3/57 | 11/58 | 5/57 |
| Application Site ReactionGeneral disorders | 5/58 | 6/57 | 8/58 | 7/57 |
| Application Site ErythemaGeneral disorders | 4/58 | 4/57 | 7/58 | 7/57 |
| MalaiseGeneral disorders | 2/58 | 2/57 | 2/58 | 4/57 |
| AnorexiaMetabolism and nutrition disorders | 0/58 | 1/57 | 1/58 | 4/57 |
3 subjects (1 for each placebo, 4.5 mg/day and 6.75 mg/day arm) were excluded by criteria
| Age, Categorical(Participants) | Placebo | 2.25 mg/Day | 4.5 mg/Day | 6.75 mg/Day | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 48 | 48 | 49 | 48 | 193 |
| >=65 years | 9 | 9 | 8 | 8 | 34 |
| Age, Continuous(years) | Placebo | 2.25 mg/Day | 4.5 mg/Day | 6.75 mg/Day | Total |
|---|---|---|---|---|---|
| Mean | 48.6 ± 13.1 | 50.6 ± 13.0 | 48.3 ± 14.1 | 51.0 ± 12.4 | 49.6 ± 13.1 |
| Sex: Female, Male(Participants) | Placebo | 2.25 mg/Day | 4.5 mg/Day | 6.75 mg/Day | Total |
|---|---|---|---|---|---|
| Female | 37 | 41 | 33 | 32 | 143 |
| Male | 20 | 16 | 24 | 24 | 84 |
| Region of Enrollment(participants) | Placebo | 2.25 mg/Day | 4.5 mg/Day | 6.75 mg/Day | Total |
|---|---|---|---|---|---|
| Japan | 57 | 57 | 57 | 56 | 227 |
The record gives a start of Jun 2008, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 4 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine
Otsuka Pharmaceutical Co., Ltd. →